- Kyverna, Metagenomi are next tests for industry’s debutants
- Industry IPO proceeds of $786 million is best start since 2021
Drug developers are capitalizing on the industry’s momentum by tapping public investors for the first time, as corporate takeovers and a welcoming market lift optimism about biotechnology.
When Kyverna Therapeutics Inc. and Metagenomi Inc. sell shares in the coming days, they’ll mark the fourth and fifth biotech initial public offerings on US exchanges in 2024. The first three raised $786 million collectively, in the strongest start for the sector since 2021, data compiled by Bloomberg show.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.